Eli Lilly shares results from QWINT trials on once-weekly insulin efsitora for type 2 diabetes EP News Bureau Jun 23, 2025 Efsitora met primary endpoints across three Phase 3 trials, showing comparable glucose control to daily basal insulin therapies
